Header Logo

Connection

Frederick Raal to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Treatment Outcome.
Frederick Raal
Connection Strength
4,555
Treatment Outcome
  1. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
    View in: PubMed
    Score: 0,197
  2. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
    View in: PubMed
    Score: 0,190
  3. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
    View in: PubMed
    Score: 0,186
  4. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
    View in: PubMed
    Score: 0,185
  5. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
    View in: PubMed
    Score: 0,170
  6. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. S Afr Med J. 2022 05 31; 112(6):426-432.
    View in: PubMed
    Score: 0,164
  7. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr. 2020 Sep/Oct; 31(5):245-251.
    View in: PubMed
    Score: 0,145
  8. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020 06 02; 141(22):1829-1831.
    View in: PubMed
    Score: 0,143
  9. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 04 16; 382(16):1520-1530.
    View in: PubMed
    Score: 0,141
  10. A pain in the neck. BMJ. 2019 Nov 21; 367:l6008.
    View in: PubMed
    Score: 0,138
  11. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 10 29; 74(17):2132-2146.
    View in: PubMed
    Score: 0,137
  12. Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovasc J Afr. 2019 Sep/Oct 23; 30(5):279-284.
    View in: PubMed
    Score: 0,136
  13. Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. J Clin Lipidol. 2019 Sep - Oct; 13(5):735-743.
    View in: PubMed
    Score: 0,134
  14. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
    View in: PubMed
    Score: 0,130
  15. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277:483-492.
    View in: PubMed
    Score: 0,127
  16. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis. 2018 10; 277:502-507.
    View in: PubMed
    Score: 0,127
  17. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018 04 07; 39(14):1162-1168.
    View in: PubMed
    Score: 0,123
  18. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
    View in: PubMed
    Score: 0,116
  19. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
    View in: PubMed
    Score: 0,114
  20. Effect of Alirocumab on Lipoprotein(a) Over =1.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol. 2017 Jan 01; 119(1):40-46.
    View in: PubMed
    Score: 0,111
  21. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
    View in: PubMed
    Score: 0,096
  22. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
    View in: PubMed
    Score: 0,096
  23. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.
    View in: PubMed
    Score: 0,092
  24. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
    View in: PubMed
    Score: 0,090
  25. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). Cardiovasc J Afr. 2013 Sep; 24(8):330-8.
    View in: PubMed
    Score: 0,089
  26. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.
    View in: PubMed
    Score: 0,084
  27. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
    View in: PubMed
    Score: 0,080
  28. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Afr. 2011 Sep-Oct; 22(5):234-40.
    View in: PubMed
    Score: 0,078
  29. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord. 2009 Apr; 7(2):83-8.
    View in: PubMed
    Score: 0,066
  30. Questioning the importance of LDL cholesterol: don't throw the baby out with the bathwater! Cardiovasc J Afr. 2008 Mar-Apr; 19(2):63-4.
    View in: PubMed
    Score: 0,061
  31. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct; 18(5):325-9.
    View in: PubMed
    Score: 0,059
  32. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
    View in: PubMed
    Score: 0,047
  33. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
    View in: PubMed
    Score: 0,047
  34. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis. 2003 Dec; 171(2):273-9.
    View in: PubMed
    Score: 0,045
  35. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.
    View in: PubMed
    Score: 0,042
  36. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):676-684.
    View in: PubMed
    Score: 0,041
  37. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
    View in: PubMed
    Score: 0,041
  38. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999 Dec 01; 84(11):1344-6, A7.
    View in: PubMed
    Score: 0,034
  39. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 03 15; 19(1):61.
    View in: PubMed
    Score: 0,033
  40. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr. 2019 Jan/Feb 23; 30(1):15-23.
    View in: PubMed
    Score: 0,032
  41. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct; 41(10):1328-1335.
    View in: PubMed
    Score: 0,032
  42. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018 10; 277:234-255.
    View in: PubMed
    Score: 0,032
  43. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
    View in: PubMed
    Score: 0,030
  44. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
    View in: PubMed
    Score: 0,030
  45. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29; 70(9):1162-1170.
    View in: PubMed
    Score: 0,029
  46. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis. 1997 Feb 28; 129(1):97-102.
    View in: PubMed
    Score: 0,028
  47. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl. 2016 Dec; 22:1-32.
    View in: PubMed
    Score: 0,028
  48. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016 Oct; 30(5):473-483.
    View in: PubMed
    Score: 0,028
  49. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2015 Nov; 35(11):2269-80.
    View in: PubMed
    Score: 0,026
  50. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
    View in: PubMed
    Score: 0,025
  51. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
    View in: PubMed
    Score: 0,023
  52. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14; 129(2):234-43.
    View in: PubMed
    Score: 0,023
  53. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
    View in: PubMed
    Score: 0,022
  54. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr. 2008 Mar-Apr; 19(2):88-94.
    View in: PubMed
    Score: 0,015
  55. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar; 197(1):400-6.
    View in: PubMed
    Score: 0,015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.